Loading...
•
Sep 30, 2021
Balchem Q3 2021 Earnings Report
Balchem reported record third-quarter sales and earnings, driven by growth across all three segments amidst macroeconomic challenges.
Key Takeaways
Balchem Corporation reported record third-quarter results, with net sales reaching $197.9 million and net earnings of $25.0 million. The company's performance reflects the strength of its global market positions and the resilience of its business model in the face of global supply chain disruptions and input cost inflation.
Net sales increased by 13.0% to $197.9 million, with record sales in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments.
GAAP net earnings rose by 16.0% to $25.0 million, resulting in GAAP earnings per share of $0.77.
Adjusted EBITDA increased by 8.8% to $48.3 million.
Cash flows from operations were $39.6 million, with free cash flow of $31.1 million.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
Balchem anticipates macroeconomic challenges, including global supply chain disruptions and input cost inflation, to persist and potentially intensify into the fourth quarter and the following year. Mitigating these impacts will be a key focus for the Balchem team.
Challenges Ahead
- Global supply chain disruptions are expected to continue and accelerate.
- Input cost inflation is expected to continue and accelerate.
- Mitigating these impacts will remain a key focus for the Balchem team.
Revenue & Expenses
Visualization of income flow from segment revenue to net income